US 11,717,517 B2
LSD dose identification
Matthias Emanuel Liechti, Oberwil (CH); and Friederike Sophie Holze, Naters (CH)
Assigned to Universitatsspital Basel, Basel (CH)
Filed by Universitätsspital Basel, Basel (CH)
Filed on Apr. 8, 2021, as Appl. No. 17/225,715.
Claims priority of provisional application 63/050,780, filed on Jul. 11, 2020.
Claims priority of provisional application 63/008,990, filed on Apr. 13, 2020.
Prior Publication US 2021/0315884 A1, Oct. 14, 2021
Int. Cl. A61K 31/48 (2006.01); A61K 31/4045 (2006.01); A61K 31/675 (2006.01); A61P 25/24 (2006.01); G01N 33/68 (2006.01); A61K 31/137 (2006.01)
CPC A61K 31/48 (2013.01) [A61K 31/137 (2013.01); A61K 31/4045 (2013.01); A61K 31/675 (2013.01); A61P 25/24 (2018.01); G01N 33/6893 (2013.01); G01N 2800/304 (2013.01); G01N 2800/52 (2013.01)] 31 Claims
OG exemplary drawing
 
1. A method of dosing and treating patients with a psychedelic, including the steps of:
administering a psychedelic at a dose chosen from the group consisting of a minidose of 21-29 μg, psychedelic dose greater than 30 μg, good effect dose of 30-100 μg, ego-dissolution dose of greater than 100 μg, and cardiovascular safe dose of 50-200 μg, wherein the dose is established through clinical study testing; and
producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes.